Clay Siegall is a legend in his right for his unwavering commitment to finding solutions to the cancer menace. The founder of Seattle Genetics has spent close to 20 years of his life researching and developing therapies for the treatment and mitigation of cancer. INSPIRERY recently had a chance to interview the legend about his past career and future plans.
How the Idea of Starting Seattle Genetics Was Born
Clay told INSPIRERY that understanding how technology and medicine would be married to obtain solutions to diseases had been his childhood dream. When he was a student, a relative of his was diagnosed with cancer. The relative had to undergo a series of chemotherapies whose side effect was a severe anemia that became an even bigger threat than cancer. Clay saw the process as brutal and vowed to find alternative cancer treatment procedures. From that experience, the dream of starting Seattle Genetics was born. It was, however, to take several years to materialize.
Money and Profitability
Making money is always a motivation for anyone starting a venture and Clay is no exemption. He, however, explained that money was not his main motivation in establishing Seattle Genetics: finding solutions for cancer was. He acknowledged that the company earns him handsome revenue through, among other avenues, selling proprietary drugs and production partnerships. That notwithstanding, it took Seattle Genetics a whole decade before realizing its first significant profits. At one point during its first years, the company was faced with a stiff capital challenge that nearly brought it to its knees. Clay was, however, able to steer it past the crisis.
About Clay Siegall
Clay Siegall is a Zoologist by training, with a degree in the field from The University of Maryland. His foundation as a researcher was developed at George Washington University from where he did his doctoral research and graduated with a Ph.D. in Genetics.
Clay initiated Seattle Genetics in 1998, and he has since then been serving as CEO and lead researcher. In his position, he has led the company in developing several FDA-approved drugs and therapies. Brentuximab vedotin is among the therapies developed by Seattle Genetics